언어선택 ENG
전체메뉴

History

Innovative Medicines based on
ImmunoModulatory Biologics

Global biotechnology company
that benefits the world

연혁
2024
08
IMBiologics Corp. announced a License Agreement with Huadong Medicine
07
IMB-402 project funded by KEIT for Materials, Parts, and Equipment
06
IMBiologics Corp. announced a License Agreement with Navigator Medicines
04
IMB-201/IMB-401: poster presentation at American Cancer Society (AACR)
02
Signing a joint research agreement with Dong-A ST using ePENDY platform technology
01
Patent registration of ePENDY platform technology in Korea
2023
12
IMB-101, Selection of the top 10 excellent projects for KDDF 2023
11
IMB-101, American College of Rheumatology (ACR) 2023 conference poster
10
MOU with China Canton Biologics: Strategic collaboration agreement based on ePENDY platform technology
07
IMB-101, Antibody Society Korea (ASK) 2023 conference presentation
07
IMB-101 : US FDA IND approval
07
Completion of 20 Bil. KRW Series B Funding
06
IMB-101 : US FDA IND submission
04
ePENDY Platform : poster presentation at American Cancer Society (AACR)
2022
12
IMB-101 : Nature biopharma dealmakers printed/online
11
MOU with Dong-A ST: research based on ePENDY platform technology
07
ePENDY Platform, Antibody Society Korea (ASK) 2022 conference presentation
03
IMB-101 project funded by KDDF(Korea Drug Development Fund)
03
The 2nd annual shareholder meeting
2021
08
Completion of 13 Bil. KRW Series A Funding by KB, Atinum, Partners, IMM and Timewise investment firms
04
Completion of the trademark application
03
The 1st annual shareholder meeting
03
Approval of the LMO facility
02
Certification of the venture company
01
Completion of 4 Bil. KRW Seed Funding led by KB investment and Atinum investment
2020
12
Certification of the company-affiliated research institute
11
Worldwide exclusive in-licensing agreement for OXTIMA(IMB-101) with HK inno.N
11
Relocation of the HQ and the research institute to Gwanggyo Central Biz Tower
10
Patent application for the IMB platform technology
09
Temporary research institute established at Gyeonggi Bio Center
08
Establishment of IMBiologics Inc.